Challenges to antagonist blockade during sustained-release naltrexone treatment

Addiction

Volumn 105, Issue 9, 2010, Pages 1633-1639

  Kunøe, Nikolaj ^a   Lobmaier, Philipp ^a   Vederhus, John Kåre ^b   Hjerkinn, Bjørg ^b   Gossop, Michael ^c   Hegstad, Solfrid ^d   Kristensen, Øistein ^b   Waal, Helge ^a  

^a Norwegian Centre for Addiction Research   (Norway)

^b SØRLANDET HOSPITAL   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Clinical trial; drug euphoria; naltrexone; opioid antagonists; opioid dependent

Indexed keywords

NALTREXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CHEMISTRY; CLINICAL TRIAL; CRIME; DELAYED RELEASE FORMULATION; DEPRESSION; DRUG IMPLANT; EUPHORIA; FEMALE; HAIR; HUMAN; INTOXICATION; MALE; MIDDLE AGED; OPIATE ADDICTION; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; SUBSTANCE ABUSE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; CRIME; DELAYED-ACTION PREPARATIONS; DEPRESSION; DRUG IMPLANTS; EUPHORIA; FEMALE; HAIR; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; OVERDOSE; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955376530     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03031.x     Document Type: Article

References (39)

1. Martin W. R., Jasinski D. R., Mansky P. A. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973 28 : 784.
2. Resnick R. B., Volavka J., Freedman A. M., Thomas M. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry 1974 131 : 646.
3. Verebey K., Volavka J., Mulé S., Resnick R.B. Naltrexone. Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976 20 : 315 328.
4. Sullivan M. A., Vosburg S. K., Comer S. D. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl) 2006 189 : 37 46.
5. Parwatikar S., Crawford J., Unverdi C. Antagonist study in St. Louis. Am J Drug Alcohol Abuse 1975 2 : 379 390.
6. Judson B. A., Carney T. M., Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend 1981 7 : 325.
7. Greenstein R. A., Arndt I. C., McLellan A. T., O'Brien C. P., Evans B. Naltrexone: a clinical perspective. J Clin Psychiatry 1984 45 : S25.
8. Guo S., Jiang Z., Wu Y. Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification. Hong Kong J Psychiatry 2001 11 : 2.
9. Comer S. D., Sullivan M. A., Yu E., Rothenberg J. L., Kleber H. D., Kampman K. et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006 63 : 210 218.
10. Sullivan M. A., Garawi F., Bisaga A., Comer S. D., Carpenter K., Raby W. N. et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007 91 : 289 292.
11. Comer S. D., Sullivan M. A., Hulse G. K. Sustained-release naltrexone: novel treatment for opioid dependence. Exp Opin Invest Drugs 2007 16 : 1285 1294.
12. Wikler A. Conditioning factors in opiate addiction and release. In : Wilner D., Kossebaum G. G., editors. Narcotics. New York : McGraw-Hill 1965, p. 85 100.
13. Carpenter K. M., Jiang H., Sullivan M. A., Bisaga A., Comer S. D., Raby W. N. et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav 2009 23 : 47 55.
14. Meyer R., Randall R., Barrington C., Mirin S., Greenberg I. Limitations of an extinction approach to narcotic antagonist treatment. In : Demetrios J., Renault P., editors. NIDA Research Monograph 9: Narcotic Antagonists: Naltrexone. Rockville, MD : US Department of Health 1976, p. 123 135.
15. Mello N. K. Behavioral pharmacology of narcotic antagonists. In : Petersen R. C., editor. NIDA Research Monograph 19: The International Challenge of Drug Abuse. Rockville, MD : US Department of Health 1978, p. 126 141.
16. Tucker T., Ritter A., Maher C., Jackson H. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev 2004 23 : 299 309.
17. Kruptisky E. M., Burakov A. M., Tsoy M. V., Egorova V. Y., Slavina T. Y., Grinenko A. Y. et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction 2007 102 : 1164 1165.
18. Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008 103 : 1399 1401.
19. Gibson A. E., Degenhardt L. J., Hall W. D. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007 186 : 152 153.
20. O'Brien C. P., Ternes J. W., Grabowski J., Ehrman R. Classically conditioned phenomena in human opiate addiction. NIDA Res Monogr 1981 37 : 107 115.
21. Gossop M. A web of dependence. Addiction 2001 96 : 677 678.
22. Shen W. K., Edwards W. D., Hammill S. C., Bailey K. R., Ballard D. J., Gersh B. J. Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol 1995 76 : 148 152.
23. Jaffe J. H. Do antagonists have a role in the treatment of opioid dependence? Addiction 2006 101 : 468 469.
24. Kunoe N., Lobmaier P., Vederhus J. K., Hjerkinn B., Hegstad S., Gossop M. et al. A randomised controlled trial of naltrexone implants after inpatient treatment for opioid dependence. Br J Psychiatry 2009 194 : 541 546.
25. Hulse G. K., Arnold-Reed D. E., O'Neil G., Chan C. T., Hansson R., O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004 9 : 59 65.
26. Ngo H. T., Arnold-Reed D. E., Hansson R. C., Tait R. J., Hulse G. K. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 : 23 8.
27. Waal H., Frogopsahl G., Olsen L., Christophersen A. S., Morland J. Naltrexone implants - duration, tolerability and clinical usefulness. A pilot study. Eur Addict Res 2006 12 : 138 144.
28. Lobmaier P., Kunoe N., Waal H. Treatment research in prison: problems and solutions in a randomized trial. Addict Res Theory 2010 18 : 1 13.
29. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992 9 : 199 213.
30. Kokkevi A., Hartgers C. EUROPASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995 1 : 208 210.
31. Beck A. T., Ward C. H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961 4 : 561 571.
32. Pavot W., Diener E., Suh E. The Temporal Satisfaction With Life Scale. J Pers Assess 1998 70 : 340 54.
33. Derogatis L. R., Lipman R. S., Rickels K., Uhlenhuth E. H., Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974 19 : 1 15.
34. Olsen L., Christophersen A. S., Frogopsahl G., Waal H., Morland J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Br J Clin Pharmacol 2004 58 : 219.
35. Hegstad S., Khiabani H. Z., Kristoffersen L., Kunøe N., Lobmaier P., Christophersen A. S. Drug screening of hair by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2008 32 : 364 372.
36. Lewis J. R., Sauro J. When 100% really isn't 100%: Improving the accuracy of small-sample estimates of completion rates. J Usability Stud 2006 1 : 136 50.
37. Ross J., Teesson M., Darke S., Lynskey M., Ali R., Ritter A. et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005 24 : 411 418. (Pubitemid 43024040)
38. Sullivan M. A., Rothenberg J. L., Vosburg S. K., Church S. H., Feldman S. J., Epstein E. M. et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict 2006 15 : 150 9.
39. Carroll K. M., Ball S. A., Nich C., O'Connor P. G., Eagan D. A., Frankforter T. L. et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001 58 : 755.